Profil
Mr. Dalen Meeter is a Chief Financial Officer at Aspen Neuroscience, Inc. Mr. Meeter was previously employed as a Chief Financial & Accounting Officer by Singular Genomics Systems, Inc. and a Senior Director-Finance by Illumina, Inc. He received his undergraduate degree from the University of California, Santa Barbara and an MBA from USC Marshall School of Business.
Aktive Positionen von Dalen Meeter
| Unternehmen | Position | Beginn |
|---|---|---|
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage regenerative medicine biotechnology company and develops autologous induced-pluripotent stem cell | Finanzdirektor/CFO | 10.03.2025 |
Ehemalige bekannte Positionen von Dalen Meeter
| Unternehmen | Position | Ende |
|---|---|---|
| SINGULAR GENOMICS SYSTEMS, INC. | Finanzdirektor/CFO | 21.02.2025 |
| ILLUMINA, INC. | Finanzdirektor/CFO | 06.01.2017 |
Ausbildung von Dalen Meeter
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Illumina, Inc.
Illumina, Inc. Medical SpecialtiesHealth Technology Operates as a biotechnology company that develops laboratory instruments | Health Technology |
University of California, Santa Barbara
University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
USC Marshall School of Business
USC Marshall School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Singular Genomics Systems, Inc.
Singular Genomics Systems, Inc. Miscellaneous Commercial ServicesCommercial Services Develops scalable spatial multiomics technology for precision diagnostics and personalized medicine | Commercial Services |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage regenerative medicine biotechnology company and develops autologous induced-pluripotent stem cell | Health Technology |
















